Open Enrollment: What It Means for PSPs and the Patients They Serve

The most useful thing to know about this year’s open enrollment is that nobody can tell you when it ends.

Medicare’s annual enrollment period runs October 15 through December 7, as always. Marketplace coverage opens November 1. The marketplace closing date is unsettled. A 2025 CMS rule would have ended it December 15 on HealthCare.gov and capped state exchanges at December 31. A federal court vacated that provision in June 2026, several states that had already moved their deadlines moved them back, and a July ruling halted the provision again on the administration’s second attempt. The vacatur is under appeal, with HHS asking for a decision by December 31.

For anyone writing patient-facing materials in the next 2 weeks, that has a practical consequence. Any piece that names a closing date may be wrong by the time it reaches a patient, and correcting it after the fact is worse than not naming it. Materials that point patients to their own plan documents and their own marketplace hold up regardless of how the appeal lands. It is a small choice made now that saves a reprint in December.

January is an HCP event before it is a patient event

Everything chosen in the fall takes effect January 1, and the version of that reset most programs plan for is the patient one: deductibles restart, out-of-pocket costs spike, affordability calls increase.

The harder one lands on the practice.

Formulary changes take effect the same day. A drug that moved tiers, picked up a step edit, or came off a formulary entirely triggers a new prior authorization for a patient who has been on continuous therapy. Patients are almost never part of that process, so the work goes to the office, and it arrives for every affected patient across every payer in the same 2 weeks.

Missing documentation is the leading avoidable cause of denial, and a case that enters the appeal cycle delays therapy restart by weeks. In mid-January, against a backlog, that compounds fast.

What separates programs here is what they did in November. Plan-specific coverage detail, in the hands of the people who actually process the paperwork, is worth more in January than at any other point in the year. So is coordinating hub and specialty pharmacy outreach cadence, because a clinic already fielding duplicate calls has no room for a PA surge on top of it.

The education gap widens in January

A patient who cannot explain their own benefit design will not connect a January bill to anything they can do about it. That is true year-round and it concentrates in January, when an entire population goes through a coverage change at once.

Pharma spends roughly $5 billion a year on patient support programs and only about 3% of eligible patients enroll. We have been saying that number out loud for a while. Open enrollment season makes the gap more visible, because the moment a patient is most confused about their coverage is also the moment they are most likely to act on clear information.

Plain-language material that arrives before the January bill does is the highest-leverage thing a program can produce this quarter. What a deductible reset means in dollars. What to do when a medication comes back not covered. What to have ready when calling.

Worth tracking through Q1

Coverage migration is the metric that tells the real story after January. How many patients moved between benefit types, and what happened to their therapy after they did, says more about program performance than an enrollment count does. It also happens to be the kind of number that makes a program read as a business enabler rather than a cost center when it goes in front of leadership.

The programs that move first here have an easier Q1. October is when that work is possible.